Tanvex BioPharma (Taiwan) Performance
| 6541 Stock | TWD 70.30 2.20 3.23% |
Tanvex BioPharma has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 0.61, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tanvex BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tanvex BioPharma is expected to be smaller as well. Tanvex BioPharma right now has a risk of 2.51%. Please validate Tanvex BioPharma downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Tanvex BioPharma will be following its existing price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Tanvex BioPharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Tanvex BioPharma may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -24.7 M |
Tanvex |
Tanvex BioPharma Relative Risk vs. Return Landscape
If you would invest 6,710 in Tanvex BioPharma on August 28, 2024 and sell it today you would earn a total of 320.00 from holding Tanvex BioPharma or generate 4.77% return on investment over 90 days. Tanvex BioPharma is generating 0.1053% of daily returns and assumes 2.5123% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than Tanvex, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Tanvex BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tanvex BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tanvex BioPharma, and traders can use it to determine the average amount a Tanvex BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0419
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | 6541 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.51 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Tanvex BioPharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tanvex BioPharma by adding it to a well-diversified portfolio.
Tanvex BioPharma Fundamentals Growth
Tanvex Stock prices reflect investors' perceptions of the future prospects and financial health of Tanvex BioPharma, and Tanvex BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tanvex Stock performance.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M | |||
| EBITDA | (1.25 B) | |||
| Cash And Equivalents | 1.65 B | |||
| Cash Per Share | 5.29 X | |||
| Debt To Equity | 0.67 % | |||
| Book Value Per Share | 5.35 X | |||
| Cash Flow From Operations | (1.39 B) | |||
| Earnings Per Share | (4.35) X | |||
| Total Asset | 4.71 B | |||
About Tanvex BioPharma Performance
Evaluating Tanvex BioPharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tanvex BioPharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tanvex BioPharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. TANVEX BIOPHARMA is traded on Taiwan Stock Exchange in Taiwan.Things to note about Tanvex BioPharma performance evaluation
Checking the ongoing alerts about Tanvex BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tanvex BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 5.41 M. Net Loss for the year was (1.54 B) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Tanvex BioPharma has accumulated about 1.65 B in cash with (1.39 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.29. | |
| Roughly 54.0% of the company shares are owned by insiders or employees |
- Analyzing Tanvex BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tanvex BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Tanvex BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tanvex BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tanvex BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tanvex BioPharma's stock. These opinions can provide insight into Tanvex BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.